Basalt Health Raises $20M in Series A Funding
NEACompany
25madisonInvestor
Basalt Health closed a $20 million Series A on Sept. 24, 2026, led by New Enterprise Associates with participation from 25madison, bringing its total capital to $24.5 million to scale its AI‑driven post‑acute care referral platform.
Deal Terms
Basalt Health announced a $20 million Series A financing on Sept. 24, 2026. The round was led by return investor New Enterprise Associates (NEA) and included 25madison as a co‑investor. The new capital lifts the company’s cumulative funding to roughly $24.5 million. Proceeds are earmarked for product expansion across additional health systems, as well as hiring in sales, marketing, implementation, and engineering.
Platform Overview
Founded in 2024, Basalt Health offers an AI‑powered platform that ingests post‑acute care referrals from fax, portals, or direct EMR integrations. The engine evaluates each referral against facility‑specific clinical criteria and surfaces placement recommendations, streamlining admissions, benefits checks, and prior authorizations. In its pilot with Lifepoint Health, median chart processing time fell from 8.5 minutes to 1.2 minutes, and the partner plans to roll the solution out to 49 more markets by the end of 2026. A parallel deployment with ScionHealth targets 62 hospitals and over 6,000 clinicians.
The company emphasizes that its AI works within existing clinical workflows rather than relying on separate chatbot interfaces. By automating document triage and decision support, Basalt aims to reduce hospital length‑of‑stay costs tied to placement delays while keeping clinicians in the loop.
Basalt’s leadership cites personal experience in nursing and a decade at Accolade as the impetus for tackling administrative friction in post‑acute care. NEA partner Blake Wu highlighted the blend of clinical impact and operational value, while 25madison’s Merrill Anovick noted the platform’s potential to extend into payer‑centric workflows, linking clinical and financial processes.
The Series A funding will also fuel geographic expansion, with the company targeting additional major health systems and exploring integration points beyond admissions, such as discharge planning and care coordination. Basalt’s growth trajectory reflects broader investor appetite for AI solutions that can be embedded in legacy health IT environments without extensive re‑engineering.
Why It Matters
Basalt’s infusion of capital accelerates its competitive positioning against other health‑tech SaaS firms that are still building AI capabilities on top of fragmented data sources. By proving measurable time‑savings in real‑world deployments, Basalt can leverage its early‑stage traction to lock in longer‑term contracts and expand its addressable market beyond acute‑care referral to broader care‑coordination workflows. Competitors that rely on stand‑alone chatbot or rule‑engine models may find it harder to match Basalt’s integrated EMR‑centric approach, potentially prompting consolidation or rapid feature roll‑outs.
For investors, the round underscores a growing confidence in niche vertical SaaS that tackles high‑cost, high‑volume administrative bottlenecks in healthcare. NEA’s repeat backing signals belief that Basalt can achieve scale‑economies and high net‑revenue retention as hospitals adopt the platform across multiple sites, setting a benchmark for future funding rounds in the AI‑health vertical.
Key Points
- Basalt Health raised $20 million in a Series A led by New Enterprise Associates with participation from 25madison
- Total capital raised to date is approximately $24.5 million
- The AI platform reduced median chart processing time from 8.5 minutes to 1.2 minutes in a Lifepoint Health pilot
- Basalt plans to expand across 49 additional Lifepoint markets and 62 ScionHealth hospitals by end‑2026
- Funding will support product expansion beyond admissions and hiring across sales, marketing, implementation, and engineering
Analysis
While the exact valuation was not disclosed, a $20 million Series A for a health‑tech SaaS platform typically implies a post‑money valuation in the $80‑$120 million range, given prevailing 4‑6x ARR multiples for early‑stage AI‑enabled solutions. Basalt’s focus on post‑acute referral addresses a $14 billion annual volume of patient transitions, a segment where automation can directly impact hospital length‑of‑stay costs. The company’s demonstrated reduction in processing time suggests strong unit economics and the potential for high net‑revenue retention as health systems embed the tool into core workflows.
The round reflects a broader trend of investors backing vertical SaaS that combine AI with deep domain integration, rather than generic chatbot layers. As hospitals continue to seek cost‑containment and operational efficiency, platforms that can ingest legacy data formats (fax, PDFs) and output actionable recommendations are likely to command premium multiples. For operators, Baseline metrics such as reduced chart time and expanded market footprints signal a scalable GTM model that can be replicated across other care‑continuum segments, including discharge planning and payer authorizations. Investors may view Basalt as a template for future funding in AI‑driven health‑system automation, where early traction can translate into rapid multiple expansion in subsequent rounds.